Patients most vulnerable to COVID-19 have pre-existing illnesses, including diabetes and heart disease. Two potential treatments in clinical trials for COVID-19 are the anti-malarial drug, hydroxychloroquine, and the antibiotic, azithromycin. These drugs can cause side-effects, including cardiac arrhythmias which can lead to heart failure, that make them inappropriate for the most vulnerable COVID-19 patients. Cardiac […]
Read More